JP2014509838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509838A5 JP2014509838A5 JP2013547811A JP2013547811A JP2014509838A5 JP 2014509838 A5 JP2014509838 A5 JP 2014509838A5 JP 2013547811 A JP2013547811 A JP 2013547811A JP 2013547811 A JP2013547811 A JP 2013547811A JP 2014509838 A5 JP2014509838 A5 JP 2014509838A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- sequence
- monomeric
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- SKWCZPYWFRTSDD-UHFFFAOYSA-N 2,3-bis(azaniumyl)propanoate;chloride Chemical compound Cl.NCC(N)C(O)=O SKWCZPYWFRTSDD-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical class OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 235000004554 glutamine Nutrition 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 235000004400 serine Nutrition 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11150323 | 2011-01-06 | ||
| EP11150323.1 | 2011-01-06 | ||
| US201161475988P | 2011-04-15 | 2011-04-15 | |
| US61/475,988 | 2011-04-15 | ||
| PCT/DK2012/050010 WO2012092934A1 (en) | 2011-01-06 | 2012-01-06 | Monomeric and multimeric immunogenic peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016216620A Division JP2017048232A (ja) | 2011-01-06 | 2016-11-04 | 多量体ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509838A JP2014509838A (ja) | 2014-04-24 |
| JP2014509838A5 true JP2014509838A5 (enExample) | 2015-02-12 |
| JP6294076B2 JP6294076B2 (ja) | 2018-03-14 |
Family
ID=43971370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547811A Expired - Fee Related JP6294076B2 (ja) | 2011-01-06 | 2012-01-06 | 多量体ペプチド |
| JP2016216620A Pending JP2017048232A (ja) | 2011-01-06 | 2016-11-04 | 多量体ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016216620A Pending JP2017048232A (ja) | 2011-01-06 | 2016-11-04 | 多量体ペプチド |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9493514B2 (enExample) |
| EP (2) | EP2661442A4 (enExample) |
| JP (2) | JP6294076B2 (enExample) |
| KR (1) | KR101993431B1 (enExample) |
| CN (1) | CN103347892B (enExample) |
| AU (1) | AU2012204955B2 (enExample) |
| BR (1) | BR112013017488A2 (enExample) |
| CA (1) | CA2821995C (enExample) |
| EA (1) | EA034031B1 (enExample) |
| MX (1) | MX346475B (enExample) |
| WO (1) | WO2012092934A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150029678A (ko) | 2012-06-06 | 2015-03-18 | 바이오노르 이뮤노 에이에스 | 백신 |
| WO2013182661A1 (en) * | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
| EP3872097A1 (en) * | 2012-10-19 | 2021-09-01 | The Council Of The Queensland Institute Of Medical Research | Improved human herpesvirus immunotherapy |
| WO2014159931A1 (en) * | 2013-03-13 | 2014-10-02 | Washington State University | Strings of epitopes useful in diagnosing and eliciting immune responses to sexually trasmitted infections |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| WO2015110666A1 (en) | 2014-01-27 | 2015-07-30 | Bionor Immuno As | Method for the vaccination against hiv |
| WO2016042131A1 (en) * | 2014-09-18 | 2016-03-24 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin | Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation |
| EP3294755B1 (en) * | 2015-05-13 | 2023-08-23 | The United States of America as represented by the Secretary of the Department of Health and Human Services | Methods and compositions for inducing an immune response using conserved element constructs |
| KR101859223B1 (ko) * | 2016-11-29 | 2018-06-01 | 단디바이오사이언스 주식회사 | 고병원성 인플루엔자 바이러스 검출용 마커 및 이의 용도 |
| WO2018141089A1 (zh) * | 2017-02-04 | 2018-08-09 | 中国医学科学院病原生物学研究所 | 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途 |
| US10677798B2 (en) | 2017-11-22 | 2020-06-09 | Washington State University | Strings of epitopes useful in diagnosing and eliciting immune responses to sexually transmitted infections |
| GB201903132D0 (en) * | 2019-03-08 | 2019-04-24 | Queens Univ Of Belfast | A peptide for the delivery of anionic materials |
| CN111221983B (zh) | 2020-01-15 | 2023-08-04 | 北京百度网讯科技有限公司 | 时序知识图谱生成方法、装置、设备和介质 |
| CN116832720B (zh) * | 2023-06-19 | 2025-11-21 | 广州聚焦生物科技有限公司 | 一种发光免疫检测的冻干微球及其制备方法 |
| CN118684745B (zh) * | 2024-06-07 | 2025-12-09 | 中国医学科学院病原生物学研究所 | 一种抗hiv-1多肽及其衍生物和应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4606918A (en) | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ATE128716T1 (de) * | 1987-11-24 | 1995-10-15 | Abbott Lab | Hiv-peptide und methoden für den nachweis von hiv. |
| ATE111485T1 (de) * | 1988-02-10 | 1994-09-15 | Immulogic Pharma Corp | Peptidbehandlung von hartnäckigen infektionskrankheiten. |
| CA1341285C (en) * | 1988-02-12 | 2001-08-14 | Chang Yi Wang | Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines |
| MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
| FI945483A7 (fi) | 1992-05-23 | 1995-01-20 | Smithkline Beecham Biologicals S A | Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| DK0735893T3 (da) | 1993-09-14 | 2009-03-09 | Pharmexa Inc | PAN DR-bindende peptider til styrkelse af immunsvaret |
| EP0979867A3 (en) | 1993-11-04 | 2007-06-13 | Innogenetics N.V. | Immunodominant human T-cell epitopes of hepatitis C virus |
| CN1099868C (zh) | 1993-11-16 | 2003-01-29 | 斯卡法玛公司 | 具有控制释放活性成分作用的囊 |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| DE69517521T2 (de) | 1994-04-08 | 2001-03-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| JPH0950531A (ja) | 1995-08-09 | 1997-02-18 | Fuji Xerox Co Ltd | 画像処理装置 |
| AU2658897A (en) | 1996-03-21 | 1997-10-10 | Epimmune, Inc. | Hla-a2.1 binding peptides and their uses |
| DK0935662T3 (da) | 1996-05-24 | 2006-03-06 | Chiron Corp | Fusionsprotein med multiple epitoper |
| US6566330B1 (en) | 1996-10-22 | 2003-05-20 | Medical University Of South Carolina Foundation Research Development | Positively charged non-natural amino acids, methods of making and using thereof in peptides |
| CN1195702A (zh) * | 1997-04-08 | 1998-10-14 | 军事医学科学院基础医学研究所 | Hiv－1多表位重组膜抗原及其表达 |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| DE69918146T2 (de) | 1998-10-05 | 2005-07-07 | Pharmexa A/S | Verfahren zur therapeutischen impfung |
| WO2000029008A2 (en) * | 1998-11-16 | 2000-05-25 | Board Of Regents, The University Of Texas System | Hiv-specific t-cell induction |
| EP1200109A4 (en) | 1999-07-19 | 2005-06-15 | Epimmune Inc | USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C |
| EP1125905A1 (en) | 2000-02-16 | 2001-08-22 | Pepscan Systems B.V. | Segment synthesis |
| GB0005703D0 (en) | 2000-03-09 | 2000-05-03 | Alpharma As | Compounds |
| JP2004522415A (ja) | 2000-09-01 | 2004-07-29 | エピミューン インコーポレーティッド | Ｈｌａ結合ペプチドおよびその使用方法 |
| NO314588B1 (no) | 2000-09-04 | 2003-04-14 | Bionor Immuno As | HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV |
| EP1195381A1 (de) | 2000-09-28 | 2002-04-10 | Immusystems GmbH | CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope |
| GB0026094D0 (en) | 2000-10-25 | 2000-12-13 | Imp College Innovations Ltd | Methods |
| AU2003236728A1 (en) | 2002-06-10 | 2003-12-22 | Algonomics N.V. | Method for predicting the binding affinity of mhc/peptide complexes |
| JP2006504687A (ja) | 2002-09-13 | 2006-02-09 | インターツェル・アクチェンゲゼルシャフト | Ｃ型肝炎ウイルスペプチドの単離方法 |
| CA2513701C (en) | 2003-01-15 | 2013-06-18 | Haruo Sugiyama | Dimerized peptide |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| EP1652858A1 (en) | 2004-10-28 | 2006-05-03 | Innogenetics N.V. | Peptides for inducing a CTL and/or HTL response to hepatitis C virus |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| US8329188B2 (en) | 2008-11-12 | 2012-12-11 | Theraclone Sciences, Inc. | Human M2e peptide immunogens |
| EP2444414A4 (en) * | 2009-05-18 | 2013-06-12 | Nat Univ Corp Tokyo Med & Dent | PEPTIDANTES FOR INDUCING ANTIBODIES FOR THE DETECTION OF THREE-DIMENSIONAL HIV STRUCTURES AND METHOD FOR THEIR SYNTHETIZATION |
| US9200065B2 (en) * | 2009-07-03 | 2015-12-01 | Bionor Immuno As | Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain |
| CN103282375B (zh) | 2010-12-02 | 2017-01-11 | 比奥诺尔免疫有限公司 | 肽支架设计 |
-
2012
- 2012-01-06 CN CN201280004745.4A patent/CN103347892B/zh active Active
- 2012-01-06 EP EP12732054.7A patent/EP2661442A4/en not_active Ceased
- 2012-01-06 AU AU2012204955A patent/AU2012204955B2/en not_active Ceased
- 2012-01-06 EA EA201391011A patent/EA034031B1/ru not_active IP Right Cessation
- 2012-01-06 BR BR112013017488A patent/BR112013017488A2/pt active Search and Examination
- 2012-01-06 US US13/978,057 patent/US9493514B2/en not_active Expired - Fee Related
- 2012-01-06 MX MX2013007918A patent/MX346475B/es active IP Right Grant
- 2012-01-06 JP JP2013547811A patent/JP6294076B2/ja not_active Expired - Fee Related
- 2012-01-06 WO PCT/DK2012/050010 patent/WO2012092934A1/en not_active Ceased
- 2012-01-06 KR KR1020137020817A patent/KR101993431B1/ko not_active Expired - Fee Related
- 2012-01-06 EP EP18150440.8A patent/EP3338798A1/en not_active Withdrawn
- 2012-01-06 CA CA2821995A patent/CA2821995C/en active Active
-
2016
- 2016-09-14 US US15/264,926 patent/US10124059B2/en not_active Expired - Fee Related
- 2016-11-04 JP JP2016216620A patent/JP2017048232A/ja active Pending